Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

University Hospital, Gasthuisberg

ClinicalTrials.gov lists University Hospital, Gasthuisberg as lead sponsor of 51 trials. It has 3 active development programs and 9 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

7 0 1996 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.

This page covers University Hospital, Gasthuisberg: 51 lead-sponsored trials and 0 legal-entity registrations.

Get the University Hospital, Gasthuisberg report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (50)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Endometriosis 6
Esophageal Neoplasms 5
Head and Neck Neoplasms 5
Infertility 5
Pain 5

Trials by start year as sponsor or collaborator (20)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2023 1
2021 1
2019 2
2018 1
2017 1
2016 3
2014 1
2013 7
2012 4

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (3)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Enteral feeding Esophageal Neoplasms Not reported 1
Enteral feeding Head and Neck Neoplasms Not reported 1
Enteral feeding Malnutrition Not reported 1

Approved assets (9)

Shown in this order: max phase first.

Approved assets
Drug Trials
Bisacodyl 1
Prucalopride 1
Polyethylene Glycol 1
Adenosine 1
Erythromycin 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
33% hit target (n=6) 60% on time (n=5)

Journals published in (73)

Shown in this order: most published in first.

Journals published in
Journal Publications
Prenatal diagnosis 8
The European respiratory journal 7
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 6
Human reproduction (Oxford, England) 5
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 5

Organization relationships (12)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Bar-Ilan University, Israel Co sponsors trial with 1
Ziekenhuis Netwerk Antwerpen (ZNA) Co sponsors trial with 1
AZ Sint-Jan AV Co sponsors trial with 1
Hospital de Jolimont Co sponsors trial with 1
Ruhr University of Bochum Co sponsors trial with 1

Latest dated events (57)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-01-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-01-16 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2021-05-22 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2019-10-15 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2019-03-25 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (23)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
CD44 Trial sponsor Named in trial inclusion criteria
CD44 Trial sponsor Named in trial inclusion criteria
DLD Trial sponsor Named in trial inclusion criteria
F2 Trial collaborator Named in trial inclusion criteria
HLA-A Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.